Peter Simons

In this new study, exposure to maternal anxiety in utero also harmed child development.

Amidst a surge in interest in psychedelic-assisted therapy, a new critique highlights serious methodological flaws, urging for a reevaluation of how these studies are conducted and interpreted.

Research undermines the prolonged use of antipsychotics in schizophrenia treatment, suggesting improved social functioning and quality of life with discontinuation.

A study involving over 8,000 patients challenges the effectiveness of depression screening in primary care settings.

About half of the large antidepressant trials are biased enough to be considered “seeding trials,” according to the researchers.

Moncrieff et al. write, “There is abundant evidence that it is the context of our lives and not the balance of our chemicals that offer the most insight into depression.”

Despite guidance that the drugs should only be used short-term, about a third of patients indicated long-term benzo use.

A new paper investigates the evidence used by the FDA in its controversial 2023 expansion of escitalopram for young kids with anxiety.

The reanalysis finds that the data supports the null finding—that tryptophan (a proxy for serotonin) is not related to depression.

A new study reviews all the various possible biomarkers for identifying ADHD—and comes up empty-handed.